

which includes at least one biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

29. Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof in at least one animal host.

30. An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof.

33. A process for identifying therapeutic avenues related to a disease state comprising: conducting an analysis as provided by the kit of claim 18; and interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof; whereby therapeutic avenues are developed.

34. The process for identifying therapeutic avenues related to a disease state in accordance

with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer
selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:
4, SEQ ID NO: 5 or at least one analyte thereof.

38. A process for regulating a disease state by controlling the presence or absence of a
biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,
SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof.

REMARKS

The foregoing Supplemental Preliminary Amendment is made so as to further bring this
application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added.
Examination on the merits is respectfully requested.